Key points from article :
Radical gene therapy that aims to drastically reduce the risk of heart attack.
Would change from a chronic care approach to a ‘one and done’ approach.
Therapy will modify genes in the liver that are involved in making low-density lipoprotein (LDL).
People with only one working copy of PCSK9 gene are remarkably resistant to heart attack.
Patients will be injected with nanolipids which use Crispr-Cas9 to disables PCSK9.
Researchers hope to trial the therapy within the next three years
Verve Therapeutics, which will develop the therapy, has received $58.5m from investors.